Tips from Other Journals

Updated Guidelines for Management of Avian Influenza

Am Fam Physician. 2007 Nov 1;76(9):1383-1386.

Background: Avian influenza (H5N1) or “bird flu” is still around, despite waning media attention. H5N1 causes more severe symptoms than other type A influenza strains. Clinical features include persistent fever, cough, lymphopenia, and progressive respiratory difficulty over three to five days. Respiratory failure develops in most cases, with an estimated mortality of 50 percent. To date, most patients have reported exposure to sick and dying poultry in regions with known H5N1 infection, but there has been limited human-to-human transmission. There is serious risk of a global pandemic if H5N1 becomes easily transmissible between humans, and family physicians could be heavily involved in the diagnosis and management of any such pandemic. The Infectious Diseases Society of America and American Thoracic Society have released joint consensus guidelines addressing the management of potential avian influenza cases.

Recommendations: Patients with influenza-like symptoms and with known exposure to poultry in H5N1-susceptible areas should be tested for H5N1 infection. Pharyngeal swabs sent for reverse-transcriptase polymerase chain reaction testing is currently the most sensitive method for confirming H5N1 infection. Other methods include nasopharyngeal swabs and other body fluid and stool testing. Convalescent-phase antibody testing can be performed, but it is not widely available. Rapid bedside tests for influenza A have been successfully used as screening tools, but they cannot distinguish between H5N1 and less severe strains.

If avian influenza is suspected, droplet precautions, respiratory isolation, and standard infection control measures should be initiated until H5N1 infection can be ruled out. Health care workers should use N-95 or higher respirators during any clinical situation in which respiratory aerosol particles could be present.

Empiric treatment of suspected H5N1-infected patients should begin immediately with the neuraminidase inhibitor oseltamivir (Tamiflu), because recently isolated H5N1 strains have been resistant to the older agents amantadine (Symmetrel) and rimantadine (Flumadine). Current adult dosing remains the same for suspected avian influenza as for “regular” influenza (i.e., 75 mg twice daily for five days). Antibiotic therapy should also be initiated to prevent development of secondary bacterial pneumonia, including Streptococcus pneumoniae and Staphylococcus aureus, which are the most common. Appropriate agents include cefotaxime (Claforan), ceftriaxone (Rocephin), or fluoroquinolones. Treatments against methicillin-resistantS. aureus (e.g., vancomycin or linezolid [Zyvox]) should be avoided, except in cases of confirmed infection or a compatible clinical situation such as shock and necrotizing pneumonia.

Conclusion: An avian influenza pandemic can stress all aspects of the health care system, and primary care physicians will play a critical role in the early detection, management, and containment of any outbreak. Maintaining a high clinical index of suspicion, especially for influenza with severe respiratory sequelae, will be crucial. Should a pandemic occur, recommendations will likely evolve as the situation progresses. Web sites for the Centers for Disease Control and Prevention (http://www.cdc.gov) and the World Health Organization (http://who.int) will be useful references in this event. Regularly updated information can also be found at http://www.pandemicflu.gov, a Web site sponsored by the U.S. Department of Health and Human Services.

Source

Mandell LA, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. January 2007;44(suppl 2)S27–72.

editor's note: These new recommendations offer a lot of common sense, and will be invaluable in a pandemic situation. Although oseltamivir is the preferred agent to treat H5N1 influenza, current supplies are inadequate to meet the demands of a widespread epidemic. However, most H5N1 strains isolated since 2004 are also susceptible to the other available neuraminidase inhibitor, zanamivir (Relenza), and the U.S. Food and Drug Administration (FDA) has been stockpiling both agents to prepare for a potential pandemic. A third neuraminidase inhibitor called peramivir is in development and has been given a “fast-track” designation by the FDA, which should expedite its application for approval. Physicians should remember that available treatments will not cure avian influenza, but they will reduce its severity and duration. Because the H5N1 strain causes more severe symptoms in general, infected patients will still require close monitoring and possible hospitalization.

The current recommendations do not address dosing of oseltamivir in children in the event of an avian influenza outbreak. However, some guidance has been offered by the Department of Health and Human Services (see accompanying table).1k.t.m.

Recommended Doses of Oseltamivir (Tamiflu) for Avian Influenza

Patient age Recommended dose*

1 to 12 years

Doses are based on patient weight as follows:

≤ 33 lb (15 kg) = 30 mg

34 to 51 lb (15 to 23 kg) = 45 mg

52 to 89 lb (23 to 40 kg) = 60 mg

> 89 lb (40 kg) = 75 mg

13 years or older

75 mg


note: Dose should be decreased in patients with creatinine clearance less than 30 mL per minute (0.5 mL per second).

*—All doses should be administered by mouth every 12 hours.

Adapted from the U.S. Department of Health and Human Services. HHS Pandemic Influenza Plan. Supplement 7: Antiviral drug distribution and use. Accessed March 15, 2007, at: http://www.hhs.gov/pandemicflu/plan/sup7.html#11.

Recommended Doses of Oseltamivir (Tamiflu) for Avian Influenza

View Table

Recommended Doses of Oseltamivir (Tamiflu) for Avian Influenza

Patient age Recommended dose*

1 to 12 years

Doses are based on patient weight as follows:

≤ 33 lb (15 kg) = 30 mg

34 to 51 lb (15 to 23 kg) = 45 mg

52 to 89 lb (23 to 40 kg) = 60 mg

> 89 lb (40 kg) = 75 mg

13 years or older

75 mg


note: Dose should be decreased in patients with creatinine clearance less than 30 mL per minute (0.5 mL per second).

*—All doses should be administered by mouth every 12 hours.

Adapted from the U.S. Department of Health and Human Services. HHS Pandemic Influenza Plan. Supplement 7: Antiviral drug distribution and use. Accessed March 15, 2007, at: http://www.hhs.gov/pandemicflu/plan/sup7.html#11.

 

REFERENCE

1. U.S. Department of Health and Human Services. HHS pandemic influenza plan. Supplement 7: Antiviral drug distribution and use. Accessed March 15, 2007, at: http://www.hhs.gov/pandemicflu/plan/sup7.html.


Copyright © 2007 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

Navigate this Article